InVivoPlus anti-mouse CTLA-4 (CD152)

Catalog number: BP0131_100mg
Brand: Bio X Cell
Packing: 100 mg
Other sizes: Other sizes available
Price: € 3662.00
Expected delivery time: 7 days
Quantity:

Product specifications for - InVivoPlus anti-mouse CTLA-4 (CD152)

Promotion: 
Promotion: The price displayed is only for academic or non-profit organizations. Please contact our helpdesk for regular prices.
Overview: 
Product group: Antibodies
Category: Primary Antibodies
Application: Neutralisation/Blocking
Species: Mouse
Host: Hamster
Clonality: Monoclonal
Isotype: IgG2
Properties: 
Molecular weight: 150 kDa
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352203
Concentration: 2-10 mg/ml
Scientific information: 
Clone ID: 9H10
Related products: 
Related products: Recommended Isotype Control(s): InVivoPlus polyclonal Syrian hamster IgG (BP0087)
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer (IP0070)
Additional information: 
Synonyms: 9H10; BP0131; CTLA4 / CD152; CTLA4; IDDM12; GSE; GRD4; CTLA-4; CELIAC3; CD152; CD; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte protein 4; cytotoxic T-lymphocyte antigen 4; cytotoxic T lymphocyte associated antigen 4 short spliced form; celiac disease 3; CD152 isoform; cytotoxic T-lymphocyte-associated protein 4; BioXCell
Gao J, Shi LZ, Zhao H, et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167(2):397-404.e9. Read more
Bartkowiak T, Singh S, Yang G, et al. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci USA. 2015;112(38):E5290-9. Read more
Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231-5. Read more
Twyman-saint victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373-7. Read more
Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL, Stephan MT. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2015;33(1):97-101. Read more
Özdemir BC, Pentcheva-hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25(6):719-34. Read more
Krummey SM, Floyd TL, Liu D, Wagener ME, Song M, Ford ML. Candida-elicited murine Th17 cells express high Ctla-4 compared with Th1 cells and are resistant to costimulation blockade. J Immunol. 2014;192(5):2495-504. Read more
Goding SR, Wilson KA, Xie Y, et al. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol. 2013;190(9):4899-909. Read more
Hervieu A, Rébé C, Végran F, et al. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol. 2013;133(2):499-508. Read more
Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17(9):1094-100. Read more